Clinical Trial Update: AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm [Phase 2]

View source ↗

Summary

Phase 2 AMT-PET monitoring study evaluating telotristat etiprate in participants with metastatic neuroendocrine neoplasms has completed and results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome
• Nonfunctional Well-differentiated Neuroendocrine Tumor

Drugs mentioned

• XERMELO (telotristat ethyl)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2025-04-10